title: A phase III randomized study comparing doxifluridine and 5-fluorouracil as supportive chemotherapy in advanced and recurrent gastric cancer.
abstract: We conducted a phase III randomized study to investigate effects of supportive chemotherapy with oral doxifluridine (group A, 75 patients) or 5-fluorouracil (group B, 75 patients) in advanced gastric cancer when intensive chemotherapy was not an option. Although there were no significant differences between the groups with regard to survival, hospital-free survival and time to progression, median values of 3 endpoints were superior in group A. Secondary analysis showed that group A patients with prior chemotherapy tended to have longer survival and hospital-free survival and significantly longer time to progression.
authors.affiliation: Department of Surgery, Nagoya National Hospital, Naka-ku, Nagoya 460-0001, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Kondo
authors.forename: J
authors.initials: J
authors.lastname: Sakamoto
authors.forename: H
authors.initials: H
authors.lastname: Nakazato
authors.forename: A
authors.initials: A
authors.lastname: Koike
authors.forename: T
authors.initials: T
authors.lastname: Kitoh
authors.forename: K
authors.initials: K
authors.lastname: Hachisuka
authors.forename: S
authors.initials: S
authors.lastname: Saji
authors.forename: J
authors.initials: J
authors.lastname: Yura
authors.forename: Y
authors.initials: Y
authors.lastname: Nimura
authors.forename: N
authors.initials: N
authors.lastname: Hamajima
authors.forename: K
authors.initials: K
authors.lastname: Katoh
authors.forename: A
authors.initials: A
authors.lastname: Yamaguchi
authors.forename: K I
authors.initials: KI
authors.lastname: Miya
authors.forename: M
authors.initials: M
authors.lastname: Yamauchi
authors.forename: I
authors.initials: I
authors.lastname: Mizuno
authors.forename: M
authors.initials: M
authors.lastname: Nagino
authors.forename: H
authors.initials: H
authors.lastname: Takagi
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D005467:Floxuridine / Q000627:therapeutic use*; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D007414:Intestinal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D016019:Survival Analysis; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D005467:Floxuridine; D005472:Fluorouracil; C025034:doxifluridine